Tiziana Life Sci PLC (TILS) Change of Adviser July 4, 2019 – Posted in: Tiziana Life Sciences (TILS) – Tags: anti-CD3, autoimmune, biotech, biotechnology, Crohn's & Colitis 360, crohns disease, Foralumab, inflammatory diseases, Kunwar Shailubhai, Monoclonal Antibody, Monoclonal Antibody Platform, neurodegenerative disease, Severe Ulcerative Colitis Patients, Stockdale Securities, tils, Tiziana Life Sciences
Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces the appointment of Shore Capital Stockbrokers Limited as Broker, with immediate effect. This follows the acquisition of Stockdale Securities Limited by Shore Capital Markets Limited.
For further enquiries:
Tiziana Life Sciences plc +44 (0)20 7493 2853
Gabriele Cerrone, Chairman and founder
Cairn Financial Advisers LLP (Nominated adviser) +44 (0)20 7213 0883
Liam Murray / Jo Turner
|
Shore Capital (Broker) Andy Crossley / Antonio Bossi
|
+44 (0)20 7601 6125 |
END